Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment from initiation, in patients with open angle glaucoma (OAG) or ocular hypertension (OHT), who do not respond sufficiently to initial topical treatment, in routine clinical practice.

开始日期2021-09-01

申办/合作机构

Santen Pharmaceutical Co., Ltd.

NCT05299593

/ Unknown status临床4期IIT

24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.

This is a phase IV, interventional, multi-center, open clinical Trial. Patients will be administered one eye drop of tafluprost/timolol fixed combination at 20:00 (+/- 1 hour), in the treatment of open angle glaucoma and ocular hypertension. The patients will suspend the treatment with latanoprost.

开始日期2020-06-04

申办/合作机构-

CTR20182196

/ Completed临床3期

一项DE-111A治疗开角型青光眼或高眼压症的随机、双盲、平行对照、多中心研究（以他氟前列素滴眼液作为对照）

以中国开角型青光眼或高眼压症患者为对象，验证DE-111A滴眼液的降眼压效果优于0.0015%他氟前列素滴眼液单独治疗，并就安全性进行比较。

开始日期2019-01-20

申办/合作机构

Laboratoire Unither SASU

[+2]

100 项与他氟前列腺素/马来酸噻吗洛尔相关的临床结果

登录后查看更多信息

100 项与他氟前列腺素/马来酸噻吗洛尔相关的转化医学

登录后查看更多信息

100 项与他氟前列腺素/马来酸噻吗洛尔相关的专利（医药）

登录后查看更多信息

项与他氟前列腺素/马来酸噻吗洛尔相关的文献（医药）

2024-12-03·Beneficial Microbes

Bacillus subtilis DE111 partially reverses endothelial dysfunction in western-diet fed mice

Article

作者: Brown, G.D. ; Wei, Y. ; Stark, G.C. ; Graham, E.L. ; Risk, B.D. ; Gentile, C.L. ; Weir, T.L. ; Zhang, M.

Abstract:

Imbalances in the gut microbiome have emerged as an important factor in endothelial dysfunction, a significant risk factor for cardiovascular disease. Thus, interventions targeting the microbiome may prove helpful in preventing or reversing this impairment. We previously reported that spore-forming Bacillus subtilis DE111 improved endothelial function in a cohort of healthy, non-obese humans after a four-week intervention. Building on these promising results, the present study sought to investigate whether administering B. subtilis DE111 could reverse endothelial dysfunction in mice with diet-induced obesity. Male C57BL/6J mice were fed a Western diet (WD; n = 24) or standard diet (SD; n = 24) for ten weeks to induce endothelial dysfunction, after which half of the animals in each group (n = 12) were allocated to receive B. subtilis DE111 (hereafter, PB) formulated into the diet for an additional eight weeks. Outcomes included endothelial-dependent arterial dilation, glucose tolerance, body weight changes, microbiota profiles, and assessments of intestinal permeability and mucosal immunity markers. Furthermore, a cell culture model of gut barrier function was used to assess the effects of PB on gut barrier integrity. PB treatment significantly attenuated WD-induced mesenteric endothelial-dependent arterial dilation, independent of changes in other cardiometabolic parameters or changes in gut barrier function. In vitro trans-epithelial electrical resistance of the Caco-2 cell culture confirmed that neither PB-conditioned media nor faecal waters from B. subtilis-treated human stool resulted in gut barrier improvements, nor did they protect against inflammation-associated barrier disruptions. Unsurprisingly, microbiota analysis revealed significant differences in Shannon’s alpha diversity of WD-fed animals compared to SD. These data suggest that PB consumption significantly attenuated WD diet-induced endothelial dysfunction; however, the underlying mechanisms of this protection were not determined. Improvement in endothelial function was independent of PB-mediated changes to body weight or gut barrier function. Further studies should explore B. subtilis-mediated immune responses or metabolite production as mechanisms underlying these endothelial protective effects.

2023-02-23·Beneficial microbes

Acute physiological effects following Bacillus subtilis DE111 oral ingestion – a randomised, double blinded, placebo-controlled study

Article

作者: Khokhlova, E. ; Buckley, M. ; Phipps, C. ; Mazhar, S. ; Colom, J. ; Brodkorb, A. ; Simon, A. ; Rea, K. ; Freitas, D. ; Deaton, J.

Previous studies using ileostomy samples from study participants demonstrated that the spore-forming probiotic Bacillus subtilis DE111® can germinate in the small intestine as early as 4 hours after ingestion. Metabolomics, proteomics and sequencing technologies, enabled further analysis of these samples for the presence of hypoglycaemic, hypolipidemic, antioxidant, anti-inflammatory and antihypertensive molecules. In the DE111 treatment group, the polyphenols trigonelline and 2,5-dihydroxybenzoic acid, orotic acid, the non-essential amino acid cystine and the lipokine 12,13-diHome were increased. DE111 also reduced acetylcholine levels in the ileostomy samples, and increased the expression of leucocyte recruiting proteins, antimicrobial peptides and intestinal alkaline phosphatases of the brush border in the small intestine. The combination of B. subtilis DE111 and the diet administered during the study increased the expression of the proteins phosphodiesterase ENPP7, ceramidase ASAH2 and the adipokine Zn-alpha-2-glycoprotein that are involved in fatty acid and lipid metabolism. Acute B. subtilis DE111 ingestion had limited detectable effect on the microbiome, with the main change being its increased presence. These findings support previous data suggesting a beneficial role of DE111 in digestion, metabolism, and immune health that appears to begin within hours of consumption.

2022-05-01·FASEB JOURNAL

RETRACTED: Bacillus Subtilis DE111 Improves Endothelial Dependent Vascular Dilation in Mice Fed a Western Diet

Article

作者: Risk, Briana D.

Vascular dysfunction often precedes the development of cardiovascular disease in which data from our lab and others suggest a role of the gut microbiome in the development of this defect. In a pilot study of healthy humans, we observed that the spore‐based probiotic, Bacillus Subtilis DE111(DE111), improved reactive hyperemia index (RHI) scores, indicating improved vascular dilation. To further explore whether DE111 impacts cardiovascular function, the current study examined its efficacy in a diet‐induced obesity model in mice. Male C57/BJ mice were fed a standard diet (SD; n=24) or Western diet (WD; n=24) for 8 weeks to induce vascular dysfunction and were then further divided such that (n=12) half of the animals on each diet received 1billion colony forming units per day (CFU/d) of DE111. Weekly body weight was measured until termination at 6 months of age. WD and WD+DE111 mice exhibited similar increases in body weight (SD: 31.2±2.3 vs WD: 47.4±3.3 and WD+DE111: 45.7±4.0) and impairments in glucose tolerance compared to SD mice (SD: 237.1±68.0 vs WD: 410±26.9 and WD+DE111: 460±116.8, p<0.05). A 28% decrease in vessel dilation was observed with mice on a WD as compared to mice on a SD after addition of the endothelial‐dependent dilator acetylcholine (AUC, 918.3±49.25, p<0.05). However, the addition of DE111 improved endothelial mediated vessel dilation in mice fed a WD+DE111 (AUC, 991.7±47.9, p<0.05). This increase was observed independent of body weight changes and improvement in glucose tolerance. In conclusion, the addition of DE111 increased endothelial‐dependent dilation in mice fed a WD. Further analyses are underway to establish the mechanisms of this gut‐vasculature crosstalk, but our animal and human studies both suggest that the novel probiotic, DE111 may support cardiovascular health.

项与他氟前列腺素/马来酸噻吗洛尔相关的新闻（医药）

2024-12-04

·蒲公英Ouryao

参比制剂目录（第85批）正式发布！

转自：国家药监局编辑：wangxinglai2004 2024年12月04日，国家药监局发布了第85批次仿制药一致性评价参比制剂目录，其中新增品种44个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第八十五批）。新增品种：培莫沙肽注射液、盐酸半胱氨酸注射液、阿昔洛韦口服混悬液、盐酸他喷他多口服溶液、氢化可的松磷酸钠口服溶液、艾地骨化醇片、普仑司特胶囊、氯苯唑酸软胶囊、注射用阿立哌唑、乳酸钠林格注射液、奥匹卡朋胶囊、对乙酰氨基酚注射液、镥[177Lu]氧奥曲肽注射液、盐酸奥洛他定鼻喷雾剂、双氯芬酸钠外用溶液、利伐沙班片、盐酸环喷托酯滴眼液、琥珀酸普芦卡必利片、他氟前列素马来酸噻吗洛尔滴眼液、利培酮口服溶液、拉西地平片、依折麦布辛伐他汀片等；仿制药参比制剂目录（第85批）

一致性评价

2023-09-12

·智慧芽新药科讯

盘点：申请上市的 GPCR 靶向药物 (上)

本文将盘点目前已在国家药品监督管理局 (NMPA) 申请上市的GPCR 靶向药物，其中相关联的热门 GPCR类靶点和药物研发机会值得关注。礼来：替尔泊肽 Tirzepatide靶点: GIPR 和 GLP-1R 适应症：（推荐阅读：一文读懂：盘点礼来公司替尔泊肽 (Tirzepatide) 用于2型糖尿病治疗的那些临床实验）Tirzepatide 是由礼来公司开发的一款新型 GIPR 和 GLP-1R 受体双重激动剂。在临床前和临床试验中，与选择性 GLP-1 受体激动剂相比，GIP/GLP-1 双重激动剂能更好地控制血糖和减轻体重，因此作为控制血糖和体重的新治疗药物受到越来越多的关注。2022年，Tirzepatide 首次在美国获批上市，用于治疗成人 II 型糖尿病，是饮食和运动的辅助疗法。随后，Tirzepatide 分别在欧盟和日本获批，用于治疗 II 型糖尿病。根据中国药物临床试验登记与信息公示平台 (http://www.chinadrugtrials.org.cn/) 公示信息，礼来公司在中国已注册进行 8 项 Tirzepatide 相关的临床研究，适应症包括2型糖尿病、超重/肥胖、降低二型糖尿病伴心血管疾病风险增加的患者的主要不良心血管事件（MACE）的复合结局、阻塞性睡眠呼吸暂停和肥胖等。由北京大学人民医院纪立农教授牵头的“在2型糖尿病患者中比较Tirzepatide与甘精胰岛素的有效性和安全性” 研究和北京大学第一医院崔一民教授牵头的“在中国2型糖尿病患者中评价Tirzepatide多次给药的药动学研究” 研究均已完成。以下为 Tirzepatide 的适应症及临床研究情况：2. ChemoCentryx：阿伐可泮 (Avacopan)靶点：C5aR （推荐阅读：GPCR3D靶点调研：C3aR和C5aR与炎症性疾病）适应症：抗中性粒细胞胞浆自身抗体相关性血管炎阿伐可泮 (Avacopan, Tavneos) 是生物制药公司ChemoCentryx发现和开发的一款首创的口服选择性补体5a受体 (C5aR) 拮抗剂。该药适用于成人患者的抗中性粒细胞胞浆自身抗体(ANCA)相关性血管炎的辅助治疗。抗中性粒细胞胞浆自身抗体相关性血管炎（AAV）是一种罕见的（估计发病率为每年十万分之三）"寡免疫性"系统性小血管炎，其典型特征是血清中存在ANCAs。AAV 的整个病程包括肉芽肿伴多血管炎（GPA）、显微镜下多血管炎（MPA）、嗜酸性粒细胞肉芽肿伴多血管炎（EGPA）和药物诱发的 AAV。尽管病理生理学很复杂，但过去约 20 年的研究已确定替代补体途径的关键作用，特别是 C5a 与 C5aR 受体在 AAV 中的相互作用。Avacopan 最早于 2021 年 9 月 27 日在日本获批上市，随后先后在美国、欧盟、加拿大和澳大利亚获批上市，用于治疗抗中性粒细胞胞浆抗体相关性血管炎、肉芽肿伴多血管炎和显微镜下多血管炎的成年患者。除此之外，靶向多项其它临床适应症，如化脓性汗腺炎和C3肾小球病等的研究工作正在进行中。3. 辉瑞：硫酸瑞美吉泮 (Rimegepant Sulfate)靶点：CGRP 受体适应症：偏头痛 (推荐阅读：偏头痛：CGRP相关新药研发)Rimegepant 是一款口服 CGRP 受体拮抗剂，用于急性治疗成人伴有或不伴有先兆的偏头痛。Rimegepant 最初由 BMS 团队开发(BMS-742413)，2016 年新成立的生物技术公司 Biohaven Pharmaceutical 从 BMS 获得 Rimegepant 的全球独家开发和商业化权利。Biohaven 团队围绕 Rimegepant 进行了一系列的临床研究和分析，并开发出衍生的鼻喷雾剂偏头痛药物 Zavegepant。根据中国药物临床试验登记与信息公示平台 (http://www.chinadrugtrials.org.cn/) 公示信息，Biohaven 公司已在中国注册3项临床试验研究，其中2项均已完成。2022年5月，辉瑞宣布斥资总计约116亿美元的现金收购 Biohaven (全球首款治疗急性偏头痛的鼻喷雾剂（辉瑞）)。Rimegepant 最早于 2020 年 2 月 27 日在美国获批上市，随后先后在以色列、阿联酋、科威特、欧盟和冰岛等国获批上市。目前，该药物正在进行慢性鼻窦炎、鼻息肉和三叉神经痛等临床试验研究。4. 远大医药： RYALTRIS (莫米松糠酸酯/盐酸奥洛他定 (Olopatadine Hydrochloride/Mometasone Furoate Monohydrate))靶点：H1R + GR适应症：季节性过敏性鼻炎RYALTRIS（莫米松糠酸酯/盐酸奥洛他定）是一款由印度药企 Glenmark 开发的新型复方处方鼻腔喷雾剂。该药同时具有激动糖皮质激素受体 (GR) 和拮抗组胺 H1 受体 (H1R) 的功效。Mometasone 是一种中等效力的合成皮质类固醇，作为糖皮质激素受体激动剂发挥作用，具有抗炎、止痒和收缩血管的特性。Olopatadine 是一款组胺 H1 受体拮抗剂，用于治疗过敏性结膜炎和鼻炎。因为组胺是引起炎症和过敏反应的主要炎症介质，Olopatadine 通过阻断组胺受体的作用而起作用。与其他抗过敏眼科药物相比，Olopatadine 不会对细胞膜造成干扰，因此具有良好的舒适性和耐受性。RYALTRIS 最早于2019年在澳大利亚获批上市，随后先后在南非、英国、美国、加拿大等国获批上市。2019 年，远大医药与 Glenmark 订立了独家授权协议，内容为Glenmark授权远大医药为中国独家销售 Ryaltris。Glenmark将负责制造和供应授权产品，而远大医药负责授权产品于中国的临床试验及注册工作，并在获批准上市后可以于中国独家销售授权产品20年。目前，全球有多款同时靶向 H1R + GR 的复方型临床候选药物处于临床研究阶段。布局该方向的不乏顶级药企，如葛兰素史克 (GSK)。5. 安进: 依瑞奈尤单抗 (Erenumab) (推荐阅读：第一款靶向GPCR的抗体药：Aimovig® (erenumab))靶点：CGRP 受体适应症：偏头痛 Erenumab 是一款由安进公司开发的人源单克隆抗体，也是 FDA 批准的首款靶向 GPCR 的单克隆抗体药物 (推荐阅读: erenumab (AMG 334) 的作用机制研究)。Erenumab 能特异性结合和拮抗降钙素基因相关肽受体 (CGRPR)，从而预防偏头痛。2017年4月，安进宣布与诺华就 Erenumab 扩大商业合作，该药物正被研究用于预防偏头痛。这项扩大的商业合作建立在诺华和安进公司于2015年在阿尔茨海默病和偏头痛领域建立的全球神经科学合作的基础上。诺华于 2019 年在中国启动两项临床研究，用于评估 Erenumab 注射液在偏头痛治疗方面的安全性和疗效。Erenumab 最早于 2018 年在美国获批上市，随后先后在澳大利亚、冰岛、挪威、瑞士、加拿大和日本等国获批上市。除偏头痛治疗外，该药物正在进行包括头痛、潮热 (推荐阅读: 首款NK3 受体拮抗剂：FDA 批准Fezolinetant用于治疗更年期潮热)、颞下颌关节功能紊乱综合征、稳定型心绞痛等等适应症的临床试验研究。6. 协和麒麟: 伊万卡塞 (Evocalcet)靶点：CaSR适应症：继发性甲状旁腺功能亢进症Evocalcet 是由日本协和麒麟制药开发的一款钙敏感受体 (CaSR) 激动剂，用于治疗高钙血症、继发性甲状旁腺功能亢进症等。协和麒麟已在中国申请进行 2 项关于 Evocalcet 的临床试验研究，用于评估该药对治疗慢性肾脏病维持性透析患者的继发性甲状旁腺功能亢进症。其中一项由广东省人民医院余学清教授牵头的 “KHK7580在继发性甲状旁腺功能亢进症患者中的Ⅲ期临床研究” 已完成。截至目前，Evocalcet 仅在日本获批上市。7. 大冢制药: 依匹哌唑 (Brexpiprazole)靶点：5-HT1A + 5-HT2A + D2R适应症：抑郁症Brexpiprazole 是一款由日本大冢制药开发的一款血清素-多巴胺活性调节剂，用于辅助治疗重度抑郁障碍、精神分裂症和阿尔茨海默病引起的痴呆症相关的躁动。Brexpiprazole 是一款非典型抗精神病药，也是一种新型 D2 多巴胺和血清素 1A 部分激动剂，被称为血清素-多巴胺活性调节剂。它对血清素、多巴胺和 α 肾上腺素能受体有很高的亲和力。Brexpiprazole 在结构上与另一款非典型抗精神病药物 Aripiprazole 非常相似，但 Brexpiprazole 与多巴胺和血清素受体的结合亲和力不同。与Aripiprazole 相比， Brexpiprazole 产生部分激动剂介导的锥体外系症状等不良反应的可能性较小，这是因为它在 D2 受体上的内在活性较低。大冢制药已在中国申请 3 项临床试验研究，其中由首都医科大学附属北京安定医院姜涛牵头的有关抑郁症治疗的 “Brexpiprazole片剂单次给药的药代动力学及耐受性和安全性研究” 已完成。Brexpiprazole 最早于 2015 年在美国获批上市，随后先后在加拿大、日本和欧盟获批上市。除抑郁症治疗外，该药物正在全球范围内进行包括躁动、精神分裂症、阿尔兹海默症和表现焦虑等多项适应症的临床测试研究。8. 参天制药: Tapcom (他氟前列腺素/马来酸噻吗洛尔 (Tafluprost/Timolol Maleate))靶点：PTGFR + βAR适应症：青光眼、高眼压症Tapcom 是由日本参天制药开发的一款他氟前列腺素 (Tafluprost) 和马来酸噻吗洛尔 (Timolol) 的复方滴眼液。Tafluprost 是一种眼科前列腺素类似物，用于降低眼压过高或开角型青光眼患者的眼压。从化学角度看，Tafluprost 是前列腺素 F2-α 的氟化类似物。Timolol 是一种非选择性β肾上腺素能受体拮抗剂，用于治疗眼压过高或开角型青光眼的眼压升高。日本参天制药先后开发了多款滴眼液产品，并在中国申请进行临床试验研究。其中，Tapcom (DE-111A) 相关研究由复旦大学附属眼耳鼻喉科医院孙兴怀教授牵头进行，评估该药物对开角型青光眼或高眼压症的疗效和安全性，题为 “评价DE-111A滴眼液的有效性和安全性的研究”，该项目已完成。Tapcom 于2013年首次在日本获批上市，其后先后在冰岛、法国、波兰、德国等国获批上市。除 Taqcom 外，全球范围内围绕 PTGFR + βAR 进行青光眼和高眼压症治疗的药物还包括以下几项：9. 武田制药: 替度鲁肽 (Teduglutide)靶点：GLP-2R适应症：短肠综合征Teduglutide 是由英国罕见病制药巨头 Shire Development 开发的一款胰高血糖素样肽-2（GLP-2）类似物，用于治疗需要肠外营养支持的短肠综合征（SBS）患者。Teduglutide 由 33 个氨基酸组成，使用经 DNA 重组技术改造的大肠杆菌菌株制造。Teduglutide 与 GLP-2 相差一个氨基酸（丙氨酸被甘氨酸取代）。这一替代的意义在于，Teduglutide 比内源性 GLP-2 的作用时间更长，并更能抵抗二肽基肽酶-4 的蛋白水解作用。Teduglutide 最早于 2012 年在欧盟获批上市，随后分别在美国和日本获批上市，用于治疗短肠综合症。2019年，武田制药豪掷460亿英镑收购 Shire Development，被称为医药界的“蛇吞象”并购，这使得武田制药跻身全球十大生物制药公司。Teduglutide 被用于临床治疗克罗恩病和肾脏疾病的临床研究也因被收购原因终止。10. 阿斯利康: Duaklir Genuair (阿地溴铵/富马酸福莫特罗 (Aclidinium Bromide/Formoterol Fumarate))靶点：M3R + β2AR适应症：慢性阻塞性肺疾病Duaklir Genuair 是由阿斯利康开发的一款复方阿地溴铵 (Aclidinium Bromide)/富马酸福莫特罗 (Formoterol Fumarate) 吸入干粉剂。该药用作一种维持性支气管扩张剂，以减轻慢性阻塞性肺病成人患者的疾病症状。其中，Aclidinium bromide 是一种新颖的长效毒蕈碱拮抗剂，Formoterol fumarate 是一种长效β2受体激动剂。Duaklir Genuair 通过干粉吸入器 Genuair (下图)给药，每日2次，是首个与单药相比使呼吸喘促表现出统计学意义显著改善的复方药。Duaklir Genuair 最早于 2012 年在欧盟获批上市，随后于2019年在美国获批上市，用于治疗慢性阻塞性肺疾病。以上文章来源于GPCR drug diacovery，作者段思研本文仅作信息交流之目的，文中观点不代表相关疾病治疗立场，也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准临床研究

2023-05-17

·Business Wire

True Health Solutions for Women’s Evolving Microbiomes: TruBiotics® Launches Women’s Probiotics

PHOENIX--( BUSINESS WIRE )-- PanTheryx , an integrative digestive and immune health company, today launches two new TruBiotics® probiotics, specifically for women— TruBiotics Women's Capsules for Digestive/Vaginal/Bone Health and TruBiotics Women's Sugar-Free Gummies with Collagen for Digestive/Urinary/Hair, Skin & Nails Health. These novel formulas were designed to target women in different stages of life and provide multi-benefit health solutions for maintaining healthy vaginal and gut microbiomes while supporting other female health concerns, such as bone, urinary tract, hair, skin, and nail health. "Most women don’t realize the importance of maintaining their gut health as it impacts so many other areas of the body. Also, 70 percent of the immune system is in the digestive tract demonstrating the importance of keeping the gut healthy,” says Dr. Keri Marshall, Chief Medical Officer of Virtu Health Solutions and Medical and Scientific Consultant to PanTheryx. “From puberty to pregnancy and through the menopausal years, a woman’s body continually goes through changes. Multi-benefit product solutions like those from TruBiotics can help give women the foundation to build a healthy gut microbiome while supporting their overall health. I’m excited to partner with TruBiotics on this launch; educating women and health care practitioners about the effectiveness and role each of these new products can play to support specific health needs.” True Innovation to Support Women’s Health TruBiotics Women’s probiotics are a unique blend of probiotics, vitamins, minerals, and herbs that support women’s overall health at different ages. When taken daily, the probiotics provide numerous benefits that support women’s evolving microbiomes and different health needs. For women concerned with vaginal health and bone density, particularly during menopause, the new TruBiotics Women's Capsules is a specially formulated, all-in-one probiotic that has been clinically studied to address these health stressors. The formula includes: Bifidobacterium animalis (BB-12®‡), one of the most scientifically studied strains of beneficial bacteria for digestive health Lactobacillus reuteri (RC-14®‡) and Lactobacillus rhamnosus (GR-1®‡), the two most clinically studied probiotic strains to help keep vaginal Ph and yeast in balance Calcium and Vitamin D3 to support bone health and optimal immune health For women taking a proactive approach to their overall and female-related health needs, TruBiotics Sugar-Free Gummies support optimal digestive health and contain cranberry for urinary health and collagen and biotin for added beauty benefits. This probiotic features: Bacillus subtilis (DE111®‡‡) – the most clinically researched bacillus probiotic for digestive and immune health 500mg of cranberry fruit extract to help guard the urinary tract against unwanted bacteria A powerful combination of Collagen, Biotin, and Vitamin C to help maintain hair, skin, and nail health Prebiotic fiber, isomalto-oligosaccharides, acts as food for and benefits the probiotics This great-tasting cranberry-raspberry gummy is the only probiotic gummy on the market with collagen that has no sugar and is free of gluten and gelatin. Understanding Women’s Evolving Health Needs In time for Women’s Health Month, the brand commissioned a survey among women, conducted by OnePoll, to better understand women’s sentiments around the most unexpected parts of aging, how their health needs change over time, and how they address them. The Understanding Aging Women’s Health Concerns and Needs survey found that over three-fourths of women (77%) noticed certain body changes over the past decade, but less than a third (30%) felt "very prepared" for them. As women mature, three in five (60%) say they are being more proactive about their everyday health concerns and are taking more vitamins/supplements than they previously did to help combat signs of aging. The survey also found: All women, no matter their age group, experienced digestive challenges as they age Women between 43 and 77 said wrinkles and weakening of eyesight (34%), thinning/graying of hair (35%), and body aches (36%) were other leading changes they noticed The top body changes that women felt were most disruptive were digestive challenges (21%), such as constipation, weight gain (20%), and memory challenges (19%) Women are not primarily relying on their primary care doctors or ObGyns to provide them with age-related health information and are turning to registered dietitians and integrative medicine practitioners (40%) as well as online health websites like WebMD and Mayo Clinic (40%) for help “As Gen X and Millennial women enter different life stages and more mature years, their microbiomes and overall wellness needs change and require different nutrients to optimize their health,” said Pam Cebulski, general manager, consumer brands, PanTheryx, distributor of TruBiotics. “This is why we created TruBiotics Women’s probiotics, to be unique solutions for women at different life stages. As a leading probiotic brand in the U.S., we are excited to bring these new, science-backed, multi-benefit formulas to market that align naturally with the proactive, health-conscious woman as her needs evolve.” Rounding out the brand’s offering for the whole family, TruBiotics Women's Capsules and TruBiotics Women's Sugar-free Gummies are now available online and in-store at select retailers nationwide. For more information about TruBiotics and its products, please visit www.trubiotics.com . ‡BB12, RC14 and GR1 are registered trademarks of Chr. Hansen A/S. ‡‡ DE111 is a registered trademark of ADM. About PanTheryx PanTheryx™ is a nutrition and biotechnology company committed to the global commercialization of health and wellness solutions for the human and animal health markets. From leading cutting-edge research to supplying best-in-class ingredients, to commercializing category-leading consumer brands, PanTheryx is dedicated to delivering revolutionary approaches for digestive, immune, and microbiome health. As the world’s largest colostrum producer, PanTheryx provides its proprietary ColostrumOne® and La Belle® Colostrum ingredients to its partners serving the global human and animal health markets. In addition to the products it develops with its partners, the PanTheryx portfolio of consumer brands includes TruBiotics®, Goodgut®, Life’s First Naturals and DiaResQ®. For more information, please visit www.pantheryx.com . Methodology This random double-opt-in survey of 2,050 U.S. women ages 18+ was commissioned by TruBiotics between April 13 and April 14, 2023. It was conducted by market research company OnePoll , whose team members are members of the Market Research Society and have corporate membership to the American Association for Public Opinion Research ( AAPOR ) and the European Society for Opinion and Marketing Research ( ESOMAR ).

100 项与他氟前列腺素/马来酸噻吗洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED51	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Santen SAS	2013-09-20
高眼压症	日本	Santen SAS	2013-09-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
开角型青光眼	申请上市	中国	参天制药（中国）有限公司	2023-02-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03612817 (Pubmed \| Expert Opin Pharmacother)	临床4期	开角型青光眼	42	Preserved latanoprost	壓築憲衊蓋積獵鏇衊廠(糧鬱夢製獵壓窪鑰鑰鹹) = Hyperemia was more common with preserved latanoprost (21.4 vs. 7.1%; P = 0.031) 蓋鑰廠夢繭顧遞窪餘蓋 (構鑰構網膚範築鹽構選 )	-	2018-12-01
AAO2016	N/A	高眼压症 \| 青光眼	1,157	Preservative-Free Fixed-Combination Tafluprost/Timolol	範願夢鑰顧衊鏇糧壓願(鏇遞網蓋襯窪願鑰窪觸) = few adverse events 範築艱艱衊壓願鹽構鑰 (鑰製鏇獵醖齋觸糧選築 )	积极	2016-10-16
ARVO2015	N/A	-	-	Taf/T FDC	遞醖獵膚蓋壓鏇網遞繭(遞遞願襯顧淵繭選遞顧) = 鬱築衊製醖衊獵艱遞窪積夢齋鑰淵膚窪鏇壓鑰 (鏇願艱顧憲糧觸廠獵糧 ) 更多	-	2015-06-01
ARVO2015	N/A	-	-	Lat/T FDC	遞醖獵膚蓋壓鏇網遞繭(遞遞願襯顧淵繭選遞顧) = 鹽築獵齋醖遞鏇壓遞構積夢齋鑰淵膚窪鏇壓鑰 (鏇願艱顧憲糧觸廠獵糧 ) 更多	-	2015-06-01
NCT01342094 (CTgov)	临床3期	开角型青光眼	166	Placebo+DE-111 (DE-111)	醖衊齋鹽鬱蓋廠簾鏇構(遞醖衊憲顧鏇構築鹽顧) = 襯獵範選獵窪網網艱壓齋襯觸鏇窪簾糧衊膚製 (廠鏇衊鏇願築膚糧廠餘, 壓窪齋製築網廠餘艱壓 ~ 醖獵膚積簾壓蓋繭顧艱) 更多	-	2015-05-15
NCT01342094 (CTgov)	临床3期	开角型青光眼	166	Timolol (Timolol)	醖衊齋鹽鬱蓋廠簾鏇構(遞醖衊憲顧鏇構築鹽顧) = 憲壓顧獵淵觸壓鑰憲鹹齋襯觸鏇窪簾糧衊膚製 (廠鏇衊鏇願築膚糧廠餘, 醖觸襯獵廠構獵製壓鹹 ~ 鏇鏇齋夢窪齋襯製鹽衊) 更多	-	2015-05-15
NCT01343082 (CTgov)	临床3期	开角型青光眼	148	Timolol+Tafluprost+DE-111	遞製糧簾獵鬱築廠鬱衊(襯鬱糧繭鑰觸夢網獵製) = 鏇積鏇襯鹽憲網觸繭範鏇鹽築醖製淵願獵簾膚 (膚遞醖積窪艱鹽襯壓積, 餘窪艱鏇艱構範遞憲蓋 ~ 壓夢鏇顧夢廠鹽襯糧願) 更多	-	2015-05-14
NCT01342081 (CTgov)	临床3期	开角型青光眼	489	Placebo+DE-111 (DE-111)	壓鏇糧構築網鬱淵鏇夢(襯鹹膚淵膚蓋襯遞選網) = 糧築壓觸膚廠選鹹顧獵鏇簾鑰繭齋鹹簾夢艱蓋 (憲鬱壓淵鑰齋膚餘範範, 築憲鬱鏇獵廠糧鏇鏇糧 ~ 築範構製鹽餘構鹽鹹衊) 更多	-	2015-05-14
NCT01342081 (CTgov)	临床3期	开角型青光眼	489	Tafluprost (Tafluprost)	壓鏇糧構築網鬱淵鏇夢(襯鹹膚淵膚蓋襯遞選網) = 獵願壓積憲壓鹹鹹顧蓋鏇簾鑰繭齋鹹簾夢艱蓋 (憲鬱壓淵鑰齋膚餘範範, 憲顧蓋願鏇鑰願淵醖窪 ~ 艱膚蓋築淵鏇鏇蓋壓襯) 更多	-	2015-05-14